Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer.

Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at ...

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...

We've discovered 3 warning signs about Y-mAbs Therapeutics. View them for free. A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful.

Y-mAbs Therapeutics, Inc.’s YMAB share price has dipped by 7.47%, which has investors questioning if this is right time to ...

Y-mAbs Therapeutics (NASDAQ:YMAB) lost ~6% on Tuesday after Bank of America downgraded the cancer drug developer to ...

Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and translational pharmacokinetics (PK) data for their CD38-SADA bispecific fusion protein at the 2025 AACR Annual Meeting in ...

BofA analyst Alec Stranahan downgraded Y-mAbs Therapeutics (YMAB) to Underperform from Neutral with a price target of $3, down from $12.Stay ...

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target dropped by HC Wainwright from $22.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage cu ...